Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Average Recommendation of “Moderate Buy” by Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has been given an average rating of “Moderate Buy” by the fifteen brokerages that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $175.00.

Several brokerages have recently commented on JAZZ. Robert W. Baird dropped their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. TD Cowen dropped their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Piper Sandler dropped their target price on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Royal Bank of Canada boosted their target price on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. lifted their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,110 shares of company stock valued at $720,160 in the last ninety days. 4.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after purchasing an additional 84,941 shares during the last quarter. LSV Asset Management lifted its position in shares of Jazz Pharmaceuticals by 4.2% during the 2nd quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock valued at $264,750,000 after acquiring an additional 99,705 shares during the period. Pacer Advisors Inc. lifted its position in shares of Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after acquiring an additional 278,465 shares during the period. Capital World Investors acquired a new position in shares of Jazz Pharmaceuticals during the 1st quarter valued at $171,943,000. Finally, Baupost Group LLC MA lifted its position in shares of Jazz Pharmaceuticals by 52.8% during the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after acquiring an additional 440,552 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $127.65 on Thursday. The firm has a 50 day moving average of $111.61 and a 200-day moving average of $110.18. The stock has a market capitalization of $7.72 billion, a PE ratio of 17.98, a PEG ratio of 1.07 and a beta of 0.57. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $134.17.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.